Ono Pharmaceutical Announces Status of Acquisition of Own Shares

Osaka, Japan - Ono Pharmaceutical Co., Ltd. (President and CEO, Gyo Sagara; 'the Company') today announced that it has acquired its own shares pursuant to the provision of Article 156 of the Companies Act, applied by replacing terms pursuant to the provision of Paragraph 3, Article 165 of the same Act.

The status of the acquisition (progress report) is as follows

Particulars

Class of shares acquired: Common stock of the Company

Total number of shares acquired: 5,037,100 shares

Total amount of acquisition cost: 12,585,948,200 yen

Period of acquisition: February 1 to 29, 2024 (execution base)

Method for acquisition: Purchased on the Tokyo Stock Exchange

Contact:

Email: customerinfo@ono-pharma.com